KO Cancer Act
- house
- senate
- president
Last progress June 10, 2025 (8 months ago)
Introduced on June 10, 2025 by Brian K. Fitzpatrick
House Votes
Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Senate Votes
Presidential Signature
AI Insights
Summary
Provides multi-year additional funding to the National Cancer Institute (NCI) by requiring annual appropriations for fiscal years 2026–2030 equal to 25% of NCI’s FY2022 appropriation, with those funds available until expended and added on top of other NCI resources. Directs the Department of Health and Human Services, working through the FDA, to complete a one-year study on causes of cancer drug shortages (economic drivers, supply chain failures, development/approval delays, and shortages of generics/biosimilars) and to report findings and recommendations to Congress within one year of enactment.
Key Points
- Appropriates to NCI each year (FY2026–FY2030) an amount equal to 25% of NCI's FY2022 appropriation.
- These additional funds are available until expended and are in addition to other NCI resources.
- Requires HHS, through the FDA, to study causes of cancer drug shortages and report to Congress within one year.
- Study must analyze economic drivers, supply-chain failures, development/approval delays, and generic/biosimilar shortages.
- Report must include recommendations and steps to address identified causes.
- Dollar value of the annual appropriations depends on the FY2022 NCI funding level (not a fixed sum in the bill).
- Funding is targeted to cancer research capacity at the federal level by boosting NCI resources over a five-year period.
- The study adds analytic burden to HHS/FDA but does not itself change regulatory approval standards or mandate supply-side actions.
Categories & Tags
Provisions
17 itemsCancer is one of the leading causes of death in the world and has touched nearly every life, either directly or indirectly.
Cancer is the cause of nearly 1 out of every 4 deaths in the United States, since 2000 totaling over 15 million American lives.
Efforts to increase awareness of cancer symptoms among patients and clinicians would lead to earlier detection and improvements in survival rates.
Scientific understanding and research lead to innovations in effective treatments, controls, and cures for cancer.
The National Cancer Institute has been a leader in finding medical breakthroughs for treatment and therapies for cancer patients.